Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.56 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.41 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.38 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ASPH | Q12797 | 1/20 | 0.38 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19021347 | 0.88 | MGAM (0.51) | MGAMHCAR2PDGFRBPDGFRAPSMD14 | |
| SCHEMBL18987942 | 0.86 | MGAM (0.50) | MGAMHCAR2PDGFRBPDGFRAPSMD14 | |
| Hydrochloric Acid SCHEMBL18987456 | 0.86 | MGAM (0.50) | MGAMHCAR2PDGFRBPDGFRAPSMD14 | |
| Bromide SCHEMBL18987913 | 0.86 | MGAM (0.50) | MGAMHCAR2PDGFRBPDGFRAPSMD14 | |
| SCHEMBL24358304 | 0.86 | MGAM (0.50) | MGAMHCAR2PDGFRBPDGFRAPSMD14 | |
| SCHEMBL23813009 | 0.86 | MGAM (0.50) | MGAMHCAR2PDGFRBPDGFRAPSMD14 | |
| SCHEMBL8519849 | 0.84 | MGAM (0.63) | MGAMHCAR2PDGFRBPDGFRAPSMD14 | |
| SCHEMBL1645675 | 0.84 | MGAM (0.47) | MGAMHCAR2PDGFRBPDGFRAPSMD14 | |
| SCHEMBL20023727 | 0.84 | PDGFRB (0.41) | MGAMPDGFRBPDGFRAHPGDSALDH1A1 | |
| SCHEMBL30447236 | 0.84 | PDGFRB (0.41) | MGAMPDGFRBPDGFRAHPGDSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3528813-B1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ABS DEV 1 INC (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20240391925-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC (US) | 2024-11-28 | — | — | US | disclosed |
| US-12077543-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2024-09-03 | — | — | US | disclosed |
| CN-116854693-A | P2X 3 And/or P2X 2/3 Compounds and methods | 阿沙纳生物科学公司 | 2023-10-10 | — | — | CN | disclosed |
| WO-2023138599-A1 | AROMATIC FUSED RING NAV1.8 INHIBITOR, AND USE THEREOF | 成都康弘药业集团股份有限公司 | 2023-07-27 | — | — | WO | disclosed |
| CN-116462662-A | Aromatic ring Nav1.8 inhibitor and application thereof | 成都康弘药业集团股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-109996546-B | P2X 3 And/or P2X 2/3 Compounds and methods | 阿沙纳生物科学公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20220227774-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2022-07-21 | — | — | US | disclosed |
| US-11339169-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339169-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2022-05-24 | — | — | US | disclosed |
| US-10174039-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180093991-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2018-04-05 | — | — | US | disclosed |
| US-20180093991-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2018-04-05 | — | — | US | disclosed |
| WO-2018064135-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC (US) | 2018-04-05 | — | — | WO | disclosed |
| EP-1189903-B1 | NOVEL BENZO[F]NAPHTHYRIDINE, PREPARATION AND COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2003-05-28 | — | — | EP | disclosed |
| US-6566362-B2 | Use as topical antibiotics | AVENTIS PHARMA S.A. (FR) | 2003-05-20 | — | — | US | disclosed |
| US-20020137741-A1 | Benzo[f]naphthyridine derivatives, their preparation and compositions containing them | AVENTIS PHARMA S.A. (FR) | 2002-09-26 | — | — | US | disclosed |
| US-6403587-B1 | AUTOIMMUNE DISEASES, ACUTE AND CHRONIC INFLAMMATORY CONDITIONS, ALLERGIC CONDITIONS, INFECTION ASSOCIATED WITH INFLAMMATION, VIRAL, TRANSPLANTATION TISSUE REJECTION, ATHEROSCLEROSIS, RESTENOSIS, HIV INFECTIVITY, AND | PFIZER INC. | 2002-06-11 | — | — | US | disclosed |
| EP-1189903-A1 | NOVEL BENZO F]NAPHTHYRIDINE, PREPARATION AND COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001002396-A1 | NOVEL BENZO[F]NAPHTHYRIDINE, PREPARATION AND COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093991-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX6, P2RX2 | MGAM 4871/4885HCAR2 433/4885PDGFRB 739/4885 |
| US-20220227774-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX6, P2RX2 | MGAM 4871/4885HCAR2 433/4885PDGFRB 739/4885 |
| US-11339169-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX6, P2RX2 | MGAM 4871/4885HCAR2 433/4885PDGFRB 739/4885 |
| US-12077543-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX6, P2RX2 | MGAM 4871/4885HCAR2 433/4885PDGFRB 739/4885 |
| US-20020137741-A1 | Benzo[f]naphthyridine derivatives, their preparation and compositions containing them | KCNQ2, KCNQ1, KCNQ4 | MGAM 3787/4885HCAR2 3665/4885PDGFRB 2602/4885 |
| US-10174039-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX6, P2RX2 | MGAM 4871/4885HCAR2 433/4885PDGFRB 739/4885 |
| US-20240391925-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX6, P2RX2 | MGAM 4871/4885HCAR2 433/4885PDGFRB 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.